Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma (Q33358263)

26 July 2017

Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma (English)

1 reference

26 July 2017

1 reference

Thierry Lesimple

1

1 reference

26 July 2017

Mohammed B Hassel

2

1 reference

26 July 2017

Daniel Gédouin

3

1 reference

26 July 2017

Eric Seigneuret

4

1 reference

26 July 2017

Béatrice Carsin

5

1 reference

26 July 2017

Abderrahmane Hamlat

6

1 reference

26 July 2017

Laurent Riffaud

7

1 reference

26 July 2017

Hélène Simon

8

1 reference

26 July 2017

Jean P Malhaire

9

1 reference

26 July 2017

Yvon Guégan

10

1 reference

26 July 2017

1 November 2003

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

65

1 reference

26 July 2017

2

1 reference

26 July 2017

141-148

1 reference

https://scigraph.springernature.com/pub.10.1023/b:neon.0000003647.66788.3b

26 July 2017

0 references

cites work

An overview of topoisomerase I-targeting agents

1 reference

12 December 2020

Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.

1 reference

12 December 2020

Interaction of ionizing radiation with topotecan in two human tumor cell lines

1 reference

12 December 2020

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

12 December 2020

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

1 reference

12 December 2020

A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas

1 reference

12 December 2020

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts

1 reference

12 December 2020

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer

1 reference

12 December 2020

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

12 December 2020

Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates

1 reference

12 December 2020

Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers

1 reference

12 December 2020

Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

1 reference

12 December 2020

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

1 reference

12 December 2020

Practical modifications of the continual reassessment method for phase I cancer clinical trials

1 reference

12 December 2020

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

12 December 2020

Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice

1 reference

12 December 2020

Brain tumor survival: results from the National Cancer Data Base

1 reference

12 December 2020

A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4.

1 reference

12 December 2020

[Concomitant chemoradiotherapy and malignant glial tumors in the adult]

1 reference

12 December 2020

Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.

1 reference

12 December 2020

Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors

1 reference

12 December 2020

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

12 December 2020

Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials

1 reference

12 December 2020

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

12 December 2020

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

12 December 2020

DNA topoisomerase inhibitors block erythropoiesis and delay hemoglobinization in vitro.

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Phase II evaluation of topotecan for pediatric central nervous system tumors.

1 reference

12 December 2020

Review of phase I clinical studies with topotecan.

1 reference

12 December 2020

Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity

1 reference

12 December 2020

Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

1 reference

12 December 2020

The role of tumor resection in the treatment of glioblastoma multiforme in adults.

1 reference

12 December 2020

10.1023/B:NEON.0000003647.66788.3B

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference